Central administration of GPR55 receptor agonist and antagonist modulates anxiety-related behaviors in rats

Fundamental and Clinical Pharmacology

Volumn 29, Issue 2, 2015, Pages 185-190

  Rahimi, Abbasali ^a   Hajizadeh Moghaddam, Akbar ^a   Roohbakhsh, Ali ^b  

^a UNIVERSITY OF MAZANDARAN   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anxiety; GPR55; Intracerebroventricular administration; Rats

Indexed keywords

CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CENTRAL NERVOUS SYSTEM AGENTS; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; ML 193; O 1602; UNCLASSIFIED DRUG; 4 (6 ISOPROPENYL 3 METHYL 2 CYCLOHEXENYL) 5 METHYLRESORCINOL; ANXIOLYTIC AGENT; CANNABINOID RECEPTOR; CYCLOHEXANE DERIVATIVE; GPR55 PROTEIN, RAT; RESORCINOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIOR; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ELEVATED PLUS MAZE TEST; LOCOMOTION; MALE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG THERAPY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MAZE TEST; MOTOR ACTIVITY; PSYCHOLOGY; WISTAR RAT;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; CYCLOHEXANES; INFUSIONS, INTRAVENTRICULAR; MALE; MAZE LEARNING; MOTOR ACTIVITY; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; RECEPTORS, G-PROTEIN-COUPLED; RESORCINOLS;

EID: 84924913888     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12099     Document Type: Article

References (27)

1. Sawzdargo M., Nguyen T., Lee D.K. et al. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res. Mol. Brain Res. (1999) 64 193-198.
2. Baker D., Pryce G., Davies W.L., Hiley C.R. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol. Sci. (2006) 27 1-4.
3. Kapur A., Zhao P., Sharir H. et al. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J. Biol. Chem. (2009) 284 29817-29827.
4. Ryberg E., Larsson N., Sjögren S. et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. (2007) 152 1092-1101.
5. Whyte L.S., Ryberg E., Sims N.A. et al. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc. Natl Acad. Sci. USA (2009) 106 16511-16516.
6. Lauckner J.E., Jensen J.B., Chen H.Y., Lu H.C., Hille B., Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl Acad. Sci. USA (2008) 105 2699-2704.
7. Oka S., Nakajima K., Yamashita A., Kishimoto S., Sugiura T. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun. (2007) 362 928-934.
8. Ramos J.A., González S., Sagredo O., Gómez-Ruiz M., Fernández-Ruiz J. Therapeutic potential of the endocannabinoid system in the brain. Mini. Rev. Med. Chem. (2005) 5 609-617.
9. Zogopoulos P., Vasileiou I., Patsouris E., Theocharis S.E. The role of endocannabinoids in pain modulation. Fundam. Clin. Pharmacol. (2013) 27 64-80.
10. Schuelert N., McDougall J.J. The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55. Neurosci. Lett. (2011) 500 72-76.
11. Wu C.S., Chen H., Sun H. et al. GPR55, a G-protein coupled receptor for lysophosphatidylinositol, plays a role in motor coordination. PLoS ONE (2013) 8 e60314.
12. Paxinos G., Watson C. The rat brain in stereotaxic coordinates, 4th edn, Academic Press, San Diego, USA, 1998.
13. Hakimizadeh E., Oryan S., Hajizadeh Moghaddam A., Shamsizadeh A., Roohbakhsh A. Endocannabinoid system and TRPV1 receptors in the dorsal hippocampus of the rats modulate anxiety-like behaviors. Iran. J. Basic. Med. Sci. (2012) 15 795-802.
14. Heynen-Genel S., Dahl R., Shi S. et al. Screening for selective ligands for GPR55 - agonists. 2010 Sep 29 [updated 2011 May 26]. Probe Reports from the NIH Molecular Libraries Program, National Center for Biotechnology Information (US), Bethesda, MD, USA, 2010.
15. Breen C., Brownjohn P.W., Ashton J.C. The atypical cannabinoid O-1602 increases hind paw sensitisation in the chronic constriction injury model of neuropathic pain. Neurosci. Lett. (2012) 508 119-122.
16. De Petrocellis L., Di Marzo V. Non-CB1., non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J. Neuroimmune. Pharmacol. (2010) 5 103-121.
17. Moreira F.A., Wotjak C.T. Cannabinoids and anxiety. Curr. Top. Behav. Neurosci. (2010) 2 429-450.
18. Cagni P., Barros M. Cannabinoid type 1 receptor ligands WIN 55, 212-2 and AM 251 alter anxiety-like behaviors of marmoset monkeys in an open-field test. Behav. Brain Res. (2013) 240 91-94.
19. Zarrindast M.R., Mahboobi S., Sadat-Shirazi M.S., Ahmadi S. Anxiolytic-like effect induced by the cannabinoid CB1 receptor agonist, arachydonilcyclopropylamide (ACPA), in the rat amygdala is mediated through the D1 and D2 dopaminergic systems. J. Psychopharmacol. (2011) 25 131-140.
20. Kinsey S.G., O'Neal S.T., Long J.Z., Cravatt B.F., Lichtman A.H. Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol. Biochem. Behav. (2011) 98 21-27.
21. Roohbakhsh A., Moghaddam A.H., Massoudi R., Zarrindast M.R. Role of dorsal hippocampal cannabinoid receptors and nitric oxide in anxiety like behaviours in rats using the elevated plus-maze test. Clin. Exp. Pharmacol. Physiol. (2007) 34 223-229.
22. Li K., Feng J.Y., Li Y.Y. et al. Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice. Pancreas (2013) 42 123-129.
23. Michalski C.W., Laukert T., Sauliunaite D. et al. Cannabinoids ameliorate pain and reduce disease pathology in cerulein-induced acute pancreatitis. Gastroenterology (2007) 132 1968-1978.
24. Nagarkatti P., Pandey R., Rieder S.A., Hegde V.L., Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future. Med. Chem. (2009) 1 1333-1349.
25. Ashton J.C. The atypical cannabinoid O-1602: targets, actions, and the central nervous system. Cent. Nerv. Syst. Agents Med. Chem. (2012) 12 233-239.
26. de Mello Schier A.R., de Oliveira Ribeiro.N.P., Coutinho D.S. et al. Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis Sativa. CNS Neurol. Disord. Drug Targets (2014) 13 953-960.
27. Console-Bram L., Brailoiu E., Brailoiu G.C., Sharir H., Abood M.E. Activation of GPR18 by cannabinoid compounds: a tale of biased agonism. Br. J. Pharmacol. (2014) 171 3908-3917.